EGFR and cancer: In many types of cancer, FASN overexpression robustly induces de novo lipogenesis, and the generated lipids are integrated into membrane lipid rafts and activate membrane receptor tyrosine kinases such as the EGFR family, which in turn results in the initiation of oncogenic signaling pathways involving cell survival, proliferation, migration, invasion, and thereby contribute to tumorigenic transformation [23].